ArticleFrontiers in oncology2026
Optimization of RNAscope for HPV mRNA detection in liquid-based cervical cytology samples.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To establish an RNAscope-based joint detection scheme compatible with liquid-based cytology (LBC) slides and staining systems, enabling simultaneous observation of cytological phenotype and HPV E6/E7 mRNA expression in cervical cancer and precancerous lesions. Methods: From March 2023 to February 2024, 115 LBC samples were collected at the Affiliated Obstetrics and Gynecology Hospital of Fudan University. Histopathological diagnosis included 30 LSIL, 33 HSIL, 29 HPV-related SCC, 8 HPV-related adenocarcinoma and 15 negative for cervical intraepithelial lesions cases. RNAscope technology, originally applied to paraffin samples, was adapted for LBC by modifying slide type selection, extending target retrieval, and enhancing permeabilization. The improved RNAscope Results: RNAscope combined with LBC showed high positive rates, 93.33% for LSIL, 96.97% for HSIL, 100.00% for SCC, and 87.50% for HPV-related adenocarcinoma. Compared with HPV PCR testing, the diagnostic concordance rate reached 95.65% (P<0.001). Figures illustrate RNAscope positive expression patterns in LSIL, HSIL, SCC and, HPV-related adenocarcinoma. Conclusion: The adaptation of RNAscope technology, originally designed for paraffin samples, enables accurate diagnosis in cervical LBC, enhances consistency with histopathology, and provides a novel diagnostic approach for cervical lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.